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Abstract
Background: The Distress Thermometer (DT) is widely recommended for screening for distress after
cancer. However, the validity of the DT in men with prostate cancer and over differing time points
from diagnosis has not been well examined.
Method: Receiver operating characteristics analyses were used to evaluate the diagnostic accuracy
of the DT compared with three commonly used standardised scales in two prospective and one cross-
sectional survey of men with prostate cancer (n= 740, 189 and 463, respectively). Comparison scales
included the Impact of Event Scale – Revised (IES-R, Study 1), the Hospital Anxiety and Depression
Scale (HADS, Study 2) and the Brief Symptom Inventory-18 (BSI-18, Study 3).
Results: Study 1: the DT showed good accuracy against the IES-R at all time points (area under
curves (AUCs) ranging from 0.84 to 0.88) and sensitivity was high (>85%). Study 2: the DT
performed well against both the anxiety and depression subscales for HADS at baseline (AUC=0.84
and 0.82, respectively), but sensitivity decreased substantially after 12 months. Study 3: validity was
high for the anxiety (AUC=0.90, sensitivity = 90%) and depression (AUC= 0.85, sensitivity = 74%)
subscales of the BSI-18 but was poorer for somatization (AUC=0.67, sensitivity = 52%). A DT cut-
off between ≥3 and ≥6 maximised sensitivity and specificity across analyses.
Conclusions: The DT is a valid tool to detect cancer-specific distress, anxiety and depression among
prostate cancer patients, particularly close to diagnosis. A cut-off of ≥4 may be optimal soon after
diagnosis, and for longer-term assessments, ≥3 was supported.
© 2013 The Authors. Psycho-Oncology published by John Wiley & Sons, Ltd.
Introduction
Screening cancer populations to detect heightened psycho-
logical distress is nowwell accepted as a desired component
of good cancer care [1]. This approach aims to efficiently
identify those patients in need of in-depth psychological
care in order to direct services to where they are most likely
to be effective [2]. In choosing a screening measure, how-
ever, there are trade-offs to be made between cost, brevity
and ease of administration and scoring, and most impor-
tantly, the effectiveness of the scale in detecting distress
with regard to scale specificity and sensitivity. The Distress
Thermometer (DT) presents as a single-item distress screen-
ing scale that has acceptable validity compared with longer
measures [3] and on the basis of brevity is well placed for
implementation in practice settings. This scale has been
found to perform well in a range of languages [4–8] and
across a number of cancer types, for example, breast [9],
blood [10], thyroid [11] and colorectal [12] cancer, and in
community as well as research settings [13]. However, the
performance of this scale in men with prostate cancer has
not been well evaluated, which is surprising given the high
prevalence of this cancer in many countries [14] and prob-
lematic given that men may express mental health problems
differently than do women [15].
Specifically, traditional notions of masculinity that
emphasise the values of being autonomous [16] and unemo-
tional (i.e. ‘boys don’t cry’) [17] may lead many men to be
reluctant to express emotion or distress, compared with
women [18]. Consistent with this, it has been proposed that
common diagnostic criteria to identify psychological disor-
ders may not be sensitive to men’s unique expression of
emotion in relation to their mental health [19–23]. This
issue is then further complicated by findings that the trajec-
tories of adjustment for men with prostate cancer over time
is heterogeneous [24], as is their response to intervention.
This means that accurately detecting distress in this patient
group at both diagnosis and across time is crucial,
increasing the importance of having a clear understanding
of the performance of the DT in this context.
© 2013 The Authors. Psycho-Oncology published by John Wiley & Sons, Ltd.
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In this regard, Roth et al. administered the DT to 121
men with prostate cancer and found the scale to be largely
acceptable to men with prostate cancer (77% evaluable
questionnaires) with the scale performing satisfactorily
by comparison with the Hospital Anxiety and Depression
Scale (HADS [25]) when applying a DT cut-off score of
≥5 [26]. This study, however, did not specifically assess
sensitivity and specificity, and the sample included mostly
men with advanced disease. More recently, Lotfi-Jam
et al. [27] administered the DT to 332 men with prostate
cancer commencing radiation therapy and found a DT
cut-off score of ≥4 identified almost all men with
HADS scores indicative of anxious or depressive
symptomatology. The scale was found to be highly
acceptable, although the prevalence of distress was low.
Again, sensitivity and specificity were not evaluated.
Importantly, according to Lotfi-Jam et al., the DT was able
to identify a group of men who were not distressed according
to the HADS, but who had unmet supportive care needs and
prostate cancer-specific quality of life decrements.
In summary, to date, most DT validation studies have
not included men with prostate cancer and have largely
applied measures of anxiety and depression as the com-
parator. In addition, the extent to which the DT is effective
along different phases of the illness trajectory is not yet
clear. Merport et al. [28] recently suggested that for long-
term survivors, the DT was not valid with poor sensitivity
as compared with the Brief Symptom Inventory-18 (BSI-
18 [29]), on the basis of the data from a mixed sample
of cancer patients who were at least 2 years post-diagnosis
(median of 9 years). These authors subsequently argued
against its use in the survivor population. We suggest that
further data from a less heterogeneous sample are needed
to draw such a conclusion.
Accordingly, the present research has three aims. First,
we sought to assess the sensitivity and specificity of the
DT in prostate cancer patients. Second, we compare the
performance of the DT in this patient group for cancer-
specific distress and also in relation to two gold standard
measures for anxiety and depression. Third, we assess
validity of the DT across time in a prospective setting to
ascertain how the measure performs in the longer term.
Methods
Participants
Study 1
These data were from a longitudinal study that included
740 (81.7% from total eligible) men diagnosed with
prostate cancer in the geographic catchment areas of
South-East and North Queensland, Australia. The sam-
ple and methods are described in detail elsewhere [30].
In brief, participants were on average 63.4 years of age
(SD = 7.5 years; range = 43.3–83.6 years) at diagnosis;
most were in a relationship (83.9%); over half (52.1%)
had tertiary or trade qualifications; approximately equal
numbers were employed (43.6%) versus retired (45.8%);
and 40% of participants reported a gross annual household
income of <$40 000, whereas nearly 25% grossed >$80
000 per annum. At recruitment to the study, the participants’
mean time since diagnosis was 25.6 days (SD=26.9), and
their median time since diagnosis was 19 days. In Study 1,
participants completed the DT [31] and the Impact of Event
Scale – Revised (IES-R) [32,33] at baseline, 12-month
(91% response) and 36-month (88% response) follow-up.
Study 2
Participants were 189 (46.9% from total eligible) Queensland
men with localised prostate cancer who had chosen or
had undergone surgical treatment. The study data were
originally from a randomised controlled trial of a couples-
based sexuality intervention for prostate cancer patients.
The sample is described in detail elsewhere [34,35]. In
brief, the mean age of the participants in the sample was
62.6 years (SD = 6.8), and approximately two-thirds
(65%) of the participants had completed university,
college, or a trade or technical certificate. Approxi-
mately 28% of participants reported a gross annual
household income of <$40 000 per annum, whereas
about 26% fell in the $40 000–$80 000 bracket and
nearly 40% reported earning more than $80 000 per
annum. At recruitment to the study, the patients’ mean
time since diagnosis was 115.2 days (SD = 110.5);
25% had already undergone surgery for their prostate
cancer and their median time since surgery was 77 days
(SD = 109.9). In Study 2, participants completed the DT
[31] and the HADS [25] at baseline and 12-month
(84% response) follow-up.
Study 3
This sample was from a randomised controlled trial com-
paring usual care to a multimodal supportive care inter-
vention for men recently diagnosed with localised
prostate cancer in Queensland, which is described else-
where [36]. Participants were 463 (69.9% from total
eligible) men diagnosed with localised prostate cancer
between September 2011 and November 2012 who were
recruited through the Queensland Cancer Registry, a popula-
tion-based register of cancer incidence. The mean age of
participants was 64.4 years (SD = 7.6), and on average,
they were 10.8 months post-diagnosis (SD=3.0, range
0.6–21.5 months). Approximately 80% of the samples were
married, 62% had completed university/college or had a
trade/technical certification, and 45% were retired with a
further 34% employed full-time. Thirty-four per cent of
the sample’s gross annual household income was
<$40 000, 27% fell in the $40 00 to $80 000 bracket and
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36% grossed >$80 00 per annum. In Study 3, participants
completed the DT [31] and the BSI-18 [29] at baseline.
Measures
Distress thermometer
The DT is widely used as a screening measure of global
psychological distress [31] and was used to assess the
current level of psychological distress experienced by
prostate cancer patients across each of the three studies
described in turn. Participants are asked how distressed
they feel on a single 11-point scale, ranging from 0 (no
distress) to 10 (extreme distress).
Impact of Event Scale – Revised
The IES-R assesses cancer-specific distress and contains three
subscales: intrusion, avoidance and hyperarousal [32,33]. A
cut-off of >33 out of a total possible score of 88 has
been recommended to provide diagnostic information
for high distress [37]. In the current study, the alpha
coefficient showed excellent internal reliability for the
total scale score across the time points (α= 0.94–0.95).
Hospital Anxiety and Depression Scale
The HADS [25] includes two subscales: Anxiety (HADS-A)
and Depression (HADS-D). We used a cut-off of ≥8 to
indicate at least mild distress on either of the subscales, as
well as a total HADS scores (HADS-T) ≥15 to indicate
clinically significant distress. Cronbach’s alpha for HADS-A,
HADS-D and HADS-T was high at baseline and
12 months (α= 0.80–0.91).
Brief Symptom Inventory-18
The BSI-18 [29] assesses current psychological distress at
baseline with three subscales: anxiety (α=0.75), depression
(α=0.85) and somatisation (α=0.63), as well as a global
severity index (GSI) score (α=0.87). Raw scores for the
three scales and the GSI are converted to t-scores. The
recommended case rules to identify respondents with clini-
cally significant symptom elevations is a GSI t-score≥ 63,
or if any two subscale t-scores are 63 or higher, according
to the BSI-18 scoring manual. However, other studies using
cancer patient samples have adopted varying cut-offs
[15,38,39]. For this study, we examined two classification
methods: t-score≥ 63 and t-score≥ 57 as an alternative
case-rule [38].
Statistical analyses
Frequencies, percentages, means and SDs were calculated
to describe each of the study samples in terms of socio-
demographic characteristics and psychological distress.
Receiver operating characteristics (ROC) analysis was then
used to evaluate the diagnostic accuracy of the DT to detect
cases identified by the IES-R (Study 1), HADS-A, HADS-D
and HADS-T (Study 2), and the BSI-18 (Study 3). This
involves plotting the fraction of true positives (sensitivity)
against the fraction of false positives (1 – specificity) at vari-
ous threshold settings for the DT. The area under the ROC
curve (AUC) quantifies the ability of the scale to discriminate
between participants with and without clinical distress and
was expressed along with a 95% confidence interval (95%
CI). An AUC of 1 represents perfect agreement between
the two scales, whereas a value of 0.5 represents a test with
no apparent accuracy relative to the established criterion.
Optimal DT thresholds were selected according to the
Youden Index [40], which is based on the vertical distance
from the line of equality to the ROC curve. Using this
method, the cut-off is selected as the point on the ROC
curve that is farthest from chance, corresponding to the
maximum value of (sensitivity + specificity 1). In addi-
tion to the AUC, sensitivity, specificity, the percentage
correctly classified along with the positive and negative
likelihood ratios were also presented. Chi-squared tests
were used to assess differences in the ROC analyses
where applicable.
Results
Study 1
Psychological distress
Participants rated their distress level on the DT at baseline
(M= 3.1, SD= 2.5), 12 months (M= 2.3, SD= 2.3) and
36 months (M= 2.3, SD= 2.2). The percentage of partici-
pants scoring above the IES-R cut-off (≥34) decreased
as the participants moved further away from their diagno-
sis [24,35]. At baseline, 10.0% of the participants were
classified as distressed, compared with 2.0% at 12 months
and 2.5% at 36 months.
Diagnostic accuracy of the DT
At baseline, the AUC was 0.87 (95% CI = 0.83–0.91) with
an optimal DT cut-off of ≥5 (Table 1 and Figure 1). Over
time, the optimal DT cut-off decreased to≥4 at 12 months
and ≥3 at 36 months, whereas the corresponding AUCs
remained high at 0.88 and 0.84, respectively. Across the
three time points, sensitivity for the optimal DT was high
(ranging from 85.7% to 92.9%) and the specificity was
acceptable (ranging from 67.0% to 77.5%). There were
no significant differences in the results between men aged
<65 years and 65 years and older at baseline (χ2 = 0.43,
df= 1, p= 0.512), 12 months (χ2 = 2.12, df = 1, p= 0.145)
or 36 months (χ2 = 0.07, df= 1, p= 0.785).
Study 2
Psychological distress
At baseline, the average DT score was 2.2 (SD= 2.2) and
decreased to 1.6 (SD= 2.2) at 12 months. For the HADS
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subscales, about a quarter (23.0%) of the participants at
baseline and 14.0% at 12 months scored above the anxiety
cut-off, whereas 6.0% at baseline and 11.0% at 12 months
were identified as reaching caseness for depression. At
baseline, 10.1% of the participants reached the HADS-T
clinical cut-off of ≥15, with a similar proportion (10.7%)
identified as clinically distressed at the 12-month
follow-up [35].
Diagnostic accuracy of the DT
When comparing the DT to HADS-T at baseline, the AUC
was 0.83 (95% CI = 0.77–0.90) with an optimal DT cut-
off of ≥3 and remained fairly stable after 12 months at
0.80, whereas the threshold increased to ≥4 (Table 1
and Figure 2). Similar results to HADS-T were observed
for both HADS-A and HADS-D at baseline. However, at
12 months, the optimal DT cut-off was ≥6 compared with
HADS-A with an AUC of 0.84 (95% CI = 0.78–0.90),
whereas for the depression subscale, the AUC fell to
0.73 (95% CI = 0.58–0.87) with a DT cut-off ≥4. Further,
from baseline to 12 months, the sensitivity of the DT
compared with the anxiety and depression subscales
lowered substantially from 73% to 57% and 73% to
47%, respectively. In contrast, specificity tended to be
higher after 12 months compared with baseline for
HADS-T and both subscales.
Study 3
Psychological distress
The average DT score was 1.95 (SD= 2.4), whereas the
average standardised BSI global severity index of partici-
pants was 45.32 (SD 8.37, range 36–72), with mean
subscale scores for somatization 47.41 (SD 6.81, range
42–81), depression 46.05 (SD 7.04, range 42–77) and
anxiety 44.99 (SD 7.38, range 39–73). Examining levels
of distress using the t-score cut-off of ≥63, 19 participants
(4.1%) reached caseness. For the subscales, 4.1% were
classified as cases for anxiety, 4.9% for depression and
4.9% for somatisation. By using the alternative classifica-
tion method of t≥ 57, 55 participants (11.8%) were
identified as a case at baseline.
Diagnostic accuracy of the DT
The AUC was 0.84 (95% CI = 0.74–0.95) for the total
score, with a DT cut-off ≥5 maximising sensitivity
(78.9%) and specificity (84.9%) (Table 1 and Figure 3).
For the subscales, the DT was more accurate in predicting
anxiety and depression than somatisation, with AUCs of
0.90, 0.85 and 0.67, respectively. Furthermore, sensitivity
ranged from 90% for anxiety down to 52% for
somatisation, whereas specificity was high (82–86%)
across each of the subscales. The selected threshold value
was DT≥ 5 on each subscale. For the alternative case-
rule, the AUC was 0.80 (95% CI = 0.74–0.87) for the total
score, and a DT cut-off of ≥4 maximised sensitivity
(63.4%) and specificity (82.8%).
Figure 1. Receiver operating characteristics curves for the Dis-
tress Thermometer versus the Impact of Event Scale – Revised, at
baseline, 1 and 3 years after diagnosis
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Discussion
In these groups of men with prostate cancer, the DT [31]
performed well at close to the time of diagnosis in terms
of specificity and sensitivity for the detection of cancer-
specific distress as well as for anxiety and depression.
Optimal cut-off points, however, were somewhat variable
for the different scales and component subscales, and time
since diagnosis did appear to affect test sensitivity for
anxiety and depression. For example, for the HADS [25],
≥3 was optimal for anxiety and ≥4 was better for depres-
sion; for the BSI-18 [38],≥5 was optimal for all subscales,
although sensitivity was poor for somatisation. As time
passed (1 year on), the DT became less sensitive as a
marker for anxiety and depression; however, it retained
high sensitivity for cancer-specific distress up to 3 years
after diagnosis. On the basis of these data, we propose that
a cut-off of ≥4 may be the best fit for the detection of
psychological distress soon after a prostate cancer diagno-
sis, but that as time passes and into the longer term (more
than 1 year after diagnosis), a cut-off of≥3 may work most
effectively as a one-off screening question that can
then be followed up with more detailed diagnostic and
needs assessment.
Most men with prostate cancer did not demonstrate high
levels of psychological distress, suggesting that many men
are psychologically resilient to their cancer experience.
Figure 2. Receiver operating characteristics curves for the Distress Thermometer versus the anxiety and depression subscales, and the to-
tal of the Hospital Anxiety and Depression Scale, at baseline and 1 year after diagnosis
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First, this raises feasibility and methodological challenges
for psychosocial intervention research that seeks to reduce
distress. Specifically, low levels of distress in this popula-
tion group may create a floor effect for interventions that
seek to reduce psychological distress [24]. From this, it
seems prudent to advise that in the future, such research
should target high distress men. However, this then
creates a practical challenge in terms of recruiting suffi-
cient numbers for studies to be adequately powered such
that larger collaborative studies may be needed across
jurisdictions. Second, although many men may report
low levels of psychological distress, long-term decrements
in domain-specific quality of life after prostate cancer are
common, particularly for sexual function [41]. For exam-
ple, many men, up to approximately 50%, report ongoing
long-term unmet supportive care needs in the areas of
psychological and sexual wellbeing [42–44]. Further,
recent data suggest men’s psychological response to pros-
tate cancer is closely related to their masculine self-esteem
[35]. Treatment for prostate cancer may impact masculine
self-esteem not only through sexual changes but also other
physical effects such as changes in muscle mass and
adiposity [45], urinary and bowel control problems, as
well as role and relationship changes [46–48]. Interven-
tions that closely articulate with men’s symptom experi-
ences, such as sexual dysfunction and bodily changes,
and that address masculine self-esteem as a potential
mediator of distress, may be most salient and effective [35].
Importantly, the present results support the use of
the DT in men with prostate cancer and provide an
empirically derived cut-off score that maximises sensi-
tivity and specificity. The addition of the DT to psy-
chosocial care plans for men with prostate cancer is
indicated. Men are less likely to seek psychosocial
support services after cancer compared with women
[49,50] and are underrepresented as users of such
services [50]. Clearly, the first critical step is to iden-
tify those who are distressed and who likely require
intervention beyond the standard support provided by
front line oncology care staff. From this, men need
to be referred to services that match their specific
concerns and level of need [51], and in this regard,
telephone-delivered nurse and peer counselling and
support are highly acceptable to men with prostate
cancer as sources of support [24,52]. However, use
of psychosocial care services by people with cancer
is predicted by positive attitudes to help-seeking that
includes the extent to which patients believe their
doctor is supportive of these services [49,53]. Hence,
if we are to effectively increase use of psychosocial
care by men with prostate cancer, screening and referral to
support will likely need the advocacy of the treating health
care team.
A limitation of our study was the relatively small number
of men who were identified as being clinically distressed,
anxious or depressed in each of our three cohorts. This
resulted in wide confidence intervals for the estimated
AUCs, making it problematic to identify significant differ-
ences in the validity of the DT over time and between
subscales, because of the level of uncertainty associated
Figure 3. Receiver operating characteristics curves for the Distress Thermometer versus the total and the anxiety, depression and soma-
tization subscales of the Brief Symptom Inventory 18 at baseline
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with the point values. However, despite the small number
of distress cases, results were generally consistent across
the three cohorts. Also, distress is a multifactorial con-
struct that has been described as encompassing emotional,
psychological, social and spiritual elements [54,55], and
this raises challenges in determining the optimal criterion
to apply when assessing test sensitivity and specificity.
Again, despite this issue, our results were consistent
across three different measurement approaches for
anxiety, depression and cancer-specific distress. Finally,
we note that compared with other scales used in the
present study, we found a relatively low reliability coeffi-
cient for the BSI-18 [29] such that caution may be needed
when considering the diagnostic accuracy of the DT for
distress expressed through physical symptoms.
In conclusion, the present study presents comprehen-
sive data showing the acceptability of the DT [31] for
screening for psychological distress after a diagnosis of
prostate cancer and across the illness trajectory. On the ba-
sis of this research, we have developed a problem list for
the DT [31] that is specific to this patient group and that,
similar to previous research [56], includes two questions
allowing the patient to prioritise key concerns for inter-
vention. Routine screening for distress in this patient
population will allow service providers to better ensure
that thoroughly focussed and in-depth psychological care
is delivered where it is most needed and at the level most
appropriate. We propose that self-management and low
intensity approaches are indicated for most men with
prostate cancer with clinically stepped-up services for
those who report high distress or need and complex prob-
lems. The application and evaluation of a tiered or stepped
care approach with this patient group is a priority for
future research and care planning.
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